REGN

Regeneron Pharmaceuticals
D

REGN

840.06
USD
27.71
(3.42%)
مفتوح الان
حجم التداول
10,978
الربح لكل سهم
47
العائد الربحي
0.46
P/E
21
حجم السوق
86,460,054,598
أصول ذات صلة الأخبار المقالات
المزيد

العنوان: Regeneron Pharmaceuticals

القطاع: الرعاية الصحية
الصناعة: Biotechnology
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approvedfor wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.